temozolomide has been researched along with Chromosome Deletion in 32 studies
Chromosome Deletion: Actual loss of portion of a chromosome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas." | 9.27 | Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. ( Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC, 2018) |
| "The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)." | 9.14 | Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009) |
| "A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)." | 9.13 | CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy." | 9.12 | Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 7.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "Only a few studies examined the effect of temozolomide (TMZ) in recurrent low-grade astrocytoma (LGA) after surgery, none of which included a homogeneous and sufficiently sized group of patients with progression after radiotherapy (RT)." | 7.77 | First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2011) |
| "Temozolomide, used for anaplastic gliomas and glioblastoma multiforme, is an oral drug that is stable under acidic, but labile under neutral and basic conditions." | 7.75 | Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. ( Beumer, JH; Egorin, MJ; Park, DM; Shah, DD, 2009) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 7.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| "Temozolomide was given 150 mg/m(2) days 1-7 and 15-21, every 28 days for 8 cycles." | 6.80 | Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H, 2015) |
| "Histology revealed an anaplastic oligodendroglioma." | 5.37 | Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide. ( Lou, X; Qiao, G; Wang, F, 2011) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 5.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas." | 5.27 | Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. ( Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC, 2018) |
| "The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)." | 5.14 | Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009) |
| "A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)." | 5.13 | CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy." | 5.12 | Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| " While temozolomide, an alkylating agent, has demonstrated a survival benefit, median survival in the past decade of patients with glioblastoma (GBM) remains an obdurate 15 months and add-on therapies have not significantly prolonged life." | 4.90 | Molecular neuro-oncology and the challenge of the blood-brain barrier. ( Aiken, R, 2014) |
| "We report a case of oligodendroglioma that had consistent histopathological features as well as a distinct change in 1p/19q status in the second recurrence, after temozolomide chemotherapy and radiotherapy." | 4.12 | Recurrent oligodendroglioma with changed 1p/19q status. ( Barresi, V; Calicchia, M; Ghimenton, C; Mafficini, A; Musumeci, A; Piredda, ML; Scarpa, A, 2022) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 3.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "Only a few studies examined the effect of temozolomide (TMZ) in recurrent low-grade astrocytoma (LGA) after surgery, none of which included a homogeneous and sufficiently sized group of patients with progression after radiotherapy (RT)." | 3.77 | First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2011) |
| "Temozolomide, used for anaplastic gliomas and glioblastoma multiforme, is an oral drug that is stable under acidic, but labile under neutral and basic conditions." | 3.75 | Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. ( Beumer, JH; Egorin, MJ; Park, DM; Shah, DD, 2009) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 3.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| " BCNU, fotemustin, and temozolomide dramatically increased the time of survival of the Hs683 oligodendroglioma-bearing mice, whereas temozolomide only induced a weak but nevertheless statistically significant increase in the U373 glioma-bearing mice." | 3.71 | Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. ( Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F, 2002) |
| "Temozolomide was given 150 mg/m(2) days 1-7 and 15-21, every 28 days for 8 cycles." | 2.80 | Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H, 2015) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Temozolomide chemotherapy was an independent index to prolong overall survival in high ABCC8 mRNA expression glioma patients, whereas in patients with low expression, there was no significant difference." | 1.56 | ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. ( Chai, R; Huang, L; Jiang, T; Li, G; Liu, Y; Wang, Y; Zhao, Z; Zhou, K, 2020) |
| "Histology revealed an anaplastic oligodendroglioma." | 1.37 | Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide. ( Lou, X; Qiao, G; Wang, F, 2011) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 1.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (37.50) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Barresi, V | 1 |
| Mafficini, A | 1 |
| Calicchia, M | 1 |
| Piredda, ML | 1 |
| Musumeci, A | 1 |
| Ghimenton, C | 2 |
| Scarpa, A | 1 |
| McDuff, SGR | 1 |
| Dietrich, J | 1 |
| Atkins, KM | 1 |
| Oh, KS | 1 |
| Loeffler, JS | 1 |
| Shih, HA | 1 |
| Richard, S | 1 |
| Tachon, G | 1 |
| Milin, S | 1 |
| Wager, M | 1 |
| Karayan-Tapon, L | 1 |
| Zhou, K | 1 |
| Liu, Y | 2 |
| Zhao, Z | 1 |
| Wang, Y | 1 |
| Huang, L | 1 |
| Chai, R | 1 |
| Li, G | 1 |
| Jiang, T | 1 |
| Izquierdo, C | 1 |
| Alentorn, A | 1 |
| Idbaih, A | 4 |
| Simó, M | 1 |
| Kaloshi, G | 2 |
| Ricard, D | 1 |
| Barritault, M | 1 |
| Meyronet, D | 1 |
| Bruna, J | 1 |
| Honnorat, J | 1 |
| Delattre, JY | 4 |
| Ducray, F | 2 |
| Abrunhosa-Branquinho, AN | 1 |
| Bar-Deroma, R | 1 |
| Collette, S | 1 |
| Clementel, E | 1 |
| Hurkmans, CW | 1 |
| Feuvret, L | 1 |
| Van Beek, K | 1 |
| van den Bent, M | 1 |
| Baumert, BG | 1 |
| Weber, DC | 1 |
| Wick, W | 1 |
| Winkler, F | 1 |
| Holdhoff, M | 1 |
| Sutera, P | 1 |
| Kalash, R | 1 |
| Flickinger, J | 1 |
| Engh, J | 1 |
| Heron, DE | 1 |
| van den Bent, MJ | 2 |
| Klein, M | 1 |
| Smits, M | 1 |
| Reijneveld, JC | 1 |
| French, PJ | 1 |
| Clement, P | 1 |
| de Vos, FYF | 1 |
| Wick, A | 1 |
| Mulholland, PJ | 1 |
| Taphoorn, MJB | 1 |
| Lewis, J | 1 |
| Weller, M | 1 |
| Chinot, OL | 1 |
| Kros, JM | 2 |
| de Heer, I | 1 |
| Verschuere, T | 1 |
| Coens, C | 1 |
| Golfinopoulos, V | 1 |
| Gorlia, T | 1 |
| Aiken, R | 1 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 1 |
| Ahluwalia, MS | 1 |
| Xie, H | 1 |
| Dahiya, S | 1 |
| Hashemi-Sadraei, N | 1 |
| Schiff, D | 1 |
| Fisher, PG | 1 |
| Chamberlain, MC | 2 |
| Pannullo, S | 1 |
| Newton, HB | 1 |
| Brewer, C | 1 |
| Wood, L | 1 |
| Prayson, R | 1 |
| Elson, P | 1 |
| Peereboom, DM | 1 |
| Speirs, CK | 1 |
| Simpson, JR | 1 |
| Robinson, CG | 1 |
| DeWees, TA | 1 |
| Tran, DD | 1 |
| Linette, G | 1 |
| Chicoine, MR | 1 |
| Dacey, RG | 1 |
| Rich, KM | 1 |
| Dowling, JL | 1 |
| Leuthardt, EC | 1 |
| Zipfel, GJ | 1 |
| Kim, AH | 1 |
| Huang, J | 1 |
| Sasaki, H | 1 |
| Hirose, Y | 1 |
| Yazaki, T | 1 |
| Kitamura, Y | 1 |
| Katayama, M | 1 |
| Kimura, T | 1 |
| Fujiwara, H | 1 |
| Toda, M | 1 |
| Ohira, T | 1 |
| Yoshida, K | 1 |
| Ohno, M | 1 |
| Narita, Y | 1 |
| Miyakita, Y | 1 |
| Matsushita, Y | 1 |
| Arita, H | 1 |
| Yonezawa, M | 1 |
| Yoshida, A | 1 |
| Fukushima, S | 1 |
| Takami, H | 1 |
| Ichimura, K | 1 |
| Shibui, S | 1 |
| Nagane, M | 1 |
| Vogelbaum, MA | 1 |
| Berkey, B | 1 |
| Peereboom, D | 1 |
| Macdonald, D | 1 |
| Giannini, C | 1 |
| Suh, JH | 1 |
| Jenkins, R | 1 |
| Herman, J | 1 |
| Brown, P | 1 |
| Blumenthal, DT | 1 |
| Biggs, C | 1 |
| Schultz, C | 1 |
| Mehta, M | 1 |
| Park, DM | 1 |
| Shah, DD | 1 |
| Egorin, MJ | 1 |
| Beumer, JH | 1 |
| DeAngelis, LM | 1 |
| Taal, W | 1 |
| Dubbink, HJ | 1 |
| Zonnenberg, CB | 1 |
| Zonnenberg, BA | 1 |
| Postma, TJ | 1 |
| Gijtenbeek, JM | 1 |
| Boogerd, W | 1 |
| Groenendijk, FH | 1 |
| Kouwenhoven, MC | 1 |
| van Marion, R | 1 |
| van Heuvel, I | 1 |
| van der Holt, B | 1 |
| Bromberg, JE | 1 |
| Sillevis Smitt, PA | 1 |
| Dinjens, WN | 1 |
| Wang, F | 1 |
| Qiao, G | 1 |
| Lou, X | 1 |
| Dittmann, LM | 1 |
| Danner, A | 1 |
| Gronych, J | 1 |
| Wolter, M | 1 |
| Stühler, K | 1 |
| Grzendowski, M | 1 |
| Becker, N | 1 |
| Bageritz, J | 1 |
| Goidts, V | 1 |
| Toedt, G | 1 |
| Felsberg, J | 1 |
| Sabel, MC | 1 |
| Barbus, S | 1 |
| Reifenberger, G | 1 |
| Lichter, P | 1 |
| Tews, B | 1 |
| Vajtai, I | 1 |
| Vassella, E | 1 |
| Hewer, E | 1 |
| Kappeler, A | 1 |
| Reinert, MM | 1 |
| Branle, F | 1 |
| Lefranc, F | 1 |
| Camby, I | 1 |
| Jeuken, J | 1 |
| Geurts-Moespot, A | 1 |
| Sprenger, S | 1 |
| Sweep, F | 1 |
| Kiss, R | 1 |
| Salmon, I | 1 |
| Hoang-Xuan, K | 2 |
| Capelle, L | 2 |
| Kujas, M | 1 |
| Taillibert, S | 2 |
| Duffau, H | 2 |
| Lejeune, J | 2 |
| Polivka, M | 2 |
| Crinière, E | 1 |
| Marie, Y | 1 |
| Mokhtari, K | 2 |
| Carpentier, AF | 1 |
| Laigle, F | 1 |
| Simon, JM | 2 |
| Cornu, P | 2 |
| Broët, P | 1 |
| Sanson, M | 3 |
| Voloschin, AD | 1 |
| Louis, DN | 1 |
| Cosgrove, GR | 1 |
| Batchelor, TT | 1 |
| Wemmert, S | 1 |
| Ketter, R | 1 |
| Rahnenführer, J | 1 |
| Beerenwinkel, N | 1 |
| Strowitzki, M | 1 |
| Feiden, W | 1 |
| Hartmann, C | 1 |
| Lengauer, T | 1 |
| Stockhammer, F | 1 |
| Zang, KD | 1 |
| Meese, E | 1 |
| Steudel, WI | 1 |
| von Deimling, A | 1 |
| Urbschat, S | 1 |
| Brandes, AA | 1 |
| Tosoni, A | 1 |
| Cavallo, G | 1 |
| Reni, M | 1 |
| Franceschi, E | 1 |
| Bonaldi, L | 1 |
| Bertorelle, R | 1 |
| Gardiman, M | 1 |
| Iuzzolino, P | 1 |
| Pession, A | 1 |
| Blatt, V | 1 |
| Ermani, M | 1 |
| Benouaich-Amiel, A | 2 |
| Diakite, F | 1 |
| Laigle-Donadey, F | 2 |
| Renard, MA | 1 |
| Iraqi, W | 1 |
| Paris, S | 1 |
| Omuro, A | 1 |
| Carpentier, A | 1 |
| Rousseau, A | 1 |
| Glantz, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial[NCT01164189] | Phase 2 | 155 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas[NCT00033280] | Phase 2 | 42 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for temozolomide and Chromosome Deletion
| Article | Year |
|---|---|
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Me | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
6 trials available for temozolomide and Chromosome Deletion
| Article | Year |
|---|---|
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chro | 2015 |
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Chromosome | 2009 |
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Ch | 2006 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; | 2008 |
23 other studies available for temozolomide and Chromosome Deletion
| Article | Year |
|---|---|
Recurrent oligodendroglioma with changed 1p/19q status.
Topics: Brain Neoplasms; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosome | 2022 |
Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemoradiotherapy, Adj | 2018 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2016 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neopl | 2008 |
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 9; Combined Modality Therapy; C | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chromosom | 2011 |
Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2011 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islan | 2012 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, | 2012 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; C | 2004 |
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromos | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X | 2008 |